遗传修饰技术在绵羊分子设计育种中的应用
|
王海涛, 李亭亭, 黄勋, 马润林, 刘秋月
|
Application of genetic modification technologies in molecular design breeding of sheep
|
Wang Haitao, Li Tingting, Huang Xun, Ma Runlin, Liu Qiuyue
|
|
表6 在绵羊、山羊和猪中进行显微注射或体细胞核移植获得个体的比率统计
|
Table 6 Rates of offspring generated by microinjection or SCNT in sheep, goats and pigs
|
|
物种 | 方法 | 基因 | 遗传修饰类型 | 移植胚胎数/ 受体数/怀孕 | 基因编辑后代/ 所有后代 | 获得后代 比率(%) | 参考文献 | 绵羊 | 原核注射 | hGH | 随机整合 | 1032/192/- | 1/73 | 7.1 | [6] | hFⅨ | 随机整合 | 67/24/11 | 6/7 | 10.4 | [10] | oGH | 随机整合 | 408/109/39 | 4/44 | 10.7 | [18] | bGH; hGHRF | 随机整合 | 842/98/33; 435/120/51 | 2/47; 9/63 | 5.6; 14.5 | [21] | bGH; hGRF | 随机整合 | 247/-/42 | 11/42 | 17.0; 9.4 | [22] | hα1AT | 随机整合 | 549/152/73 | 5/113 | 20.6 | [23] | hBCFVIII | 随机整合 | 1145/454/276 | 13/434 | 37.9 | [25] | CAT | 随机整合 | 371/76/- | 4/31 | 8.4 | [26] | HTT | 随机整合 | 413/138/- | 6/150 | 36.3 | [27] | MSTN | Cas9敲除 | 213/55/31 | 2/35 | 16.4 | [50] | MSTN、ASIP和BCO2 | Cas9敲除 | 578/82/77 | 35/36 | 7.3 | [51] | SOCS2 | BE3点突变 | 53/8/3 | 3/4 | 7.5 | [67] | ASIP | Cas9敲除 | 92/60/6 | 5/6 | 6.5 | [58] | BMPR1B | Cas9点突变 | 279/39/16 | 7/21 | 7.5 | [59] | FGF5 | 基因敲除 | 100/53/14 | 3/18 | 18 | [62] | FGF5 | 基因敲除 | 63/43/18 | 20/23 | 36.5 | [63] | 徒手克隆 | fat-1 | 随机整合 | 53/29/4 | 3/3 | 5.7 | [80] | 体细胞 核移植 | AAT | 定点插入 | 80/42/20 | 13/14 | 17.5 | [31] | oTLR4 | 随机整合 | 859/113/12; 1009/108/7 | 9/9 | 0.7; 0.3 | [32] | fat-1 | 随机整合 | 128/16/3; 147/20/3 | 5/5 | 1.6; 2.0 | [33] | MSTN | TALEN敲除 | 70/5/1 | 1/1 | 1.4 | [48] | MSTN | TALEN敲除 | 282/37/28 | 13/23 | 1.4 | [49] | 山羊 | 原核注射 | MSTN | Cas9敲除 | 416/137/64 | 26/93 | 22.4 | [85] | MSTN | Cas9敲除 | 18/5/3 | 1/4 | 22.2 | [86] | FGF5 | BE3点突变 | 22/7/3 | 5/5 | 22.7 | [87] | BLG (β-lactoglobulin) | Cas9敲除 | 103/67/18 | 4 | 25.2 | [88] | GDF9 | Cas9敲除 | 56/17/13 | 6/8 | 32.1 | [89] | 山羊 | 原核注射 | MSTN | TALEN敲除 | 403/29/7 | 3/3 | 0.7 | [90] | MSTN | Cas9敲除 | 269/21/7 | 3/3 | 2.2 | [91] | EDAR (ectodysplasin receptor) | Cas9敲除 | 257/79/5 | 2/6 | 2.3 | [92] | 猪 | 体细胞 核移植 | - | 纯体细胞克隆 | 586/10/2 | 0/7 | 1.2 | [93] | LDLR (low-density lipoprotein receptor) | 敲除 | 2276/18/9 | 57/57 | 2.5 | [94] | PPARγ | ZFN敲除 | 1134/8/4 | 2/10 | 0.2 | [95] | GGTA1 | TALEN敲除 | 2411/12/9 | 30/30 | 1.2 | [96] | FBXO40 | Cas9敲除 | 5424/16/7 | 17/17 | 0.3 | [97] | CD163 | Cas9敲除 | 2192/6/4 | 26/26 | 1.2 | [98] | 显微注射 | DMD (henne muscle dystrophy) | Cas9敲除 | 98/8/1 | 1/2 | 2.0 | [99] | TMPRSS2 (ransmembrane protease, serine S1, member 2) | Cas9敲除 | 135/2/2 | 12/12 | 8.8 | [100] | SRY (sex determining region Y) | Cas9敲除 | 66/4/2 | 12/12 | 18.2 | [101] | NANOS2 | Cas9敲除 | 84/4/3 | 18/18 | 21.4 | [102] | GGTA1 | Cas9敲除 | 94/4/2 | 4/15 | 16.0 | [103] |
|
|
|